GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neon Therapeutics Inc (NAS:NTGN) » Definitions » Asset Turnover

Neon Therapeutics (Neon Therapeutics) Asset Turnover : 0.00 (As of Mar. 2020)


View and export this data going back to 2018. Start your Free Trial

What is Neon Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Neon Therapeutics's Revenue for the three months ended in Mar. 2020 was $0.00 Mil. Neon Therapeutics's Total Assets for the quarter that ended in Mar. 2020 was $38.89 Mil. Therefore, Neon Therapeutics's Asset Turnover for the quarter that ended in Mar. 2020 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Neon Therapeutics's annualized ROE % for the quarter that ended in Mar. 2020 was -302.83%. It is also linked to ROA % through Du Pont Formula. Neon Therapeutics's annualized ROA % for the quarter that ended in Mar. 2020 was -170.73%.


Neon Therapeutics Asset Turnover Historical Data

The historical data trend for Neon Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neon Therapeutics Asset Turnover Chart

Neon Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19
Asset Turnover
- - - -

Neon Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Neon Therapeutics's Asset Turnover

For the Biotechnology subindustry, Neon Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neon Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neon Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Neon Therapeutics's Asset Turnover falls into.



Neon Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Neon Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2019 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2019 )/( (Total Assets (A: Dec. 2018 )+Total Assets (A: Dec. 2019 ))/ count )
=0/( (114.088+46.372)/ 2 )
=0/80.23
=0.00

Neon Therapeutics's Asset Turnover for the quarter that ended in Mar. 2020 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2020 )/( (Total Assets (Q: Dec. 2019 )+Total Assets (Q: Mar. 2020 ))/ count )
=0/( (46.372+31.402)/ 2 )
=0/38.887
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Neon Therapeutics  (NAS:NTGN) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Neon Therapeutics's annulized ROE % for the quarter that ended in Mar. 2020 is

ROE %**(Q: Mar. 2020 )
=Net Income/Total Stockholders Equity
=-66.392/21.924
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-66.392 / 0)*(0 / 38.887)*(38.887/ 21.924)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.7737
=ROA %*Equity Multiplier
=-170.73 %*1.7737
=-302.83 %

Note: The Net Income data used here is four times the quarterly (Mar. 2020) net income data. The Revenue data used here is four times the quarterly (Mar. 2020) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Neon Therapeutics's annulized ROA % for the quarter that ended in Mar. 2020 is

ROA %(Q: Mar. 2020 )
=Net Income/Total Assets
=-66.392/38.887
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-66.392 / 0)*(0 / 38.887)
=Net Margin %*Asset Turnover
= %*0
=-170.73 %

Note: The Net Income data used here is four times the quarterly (Mar. 2020) net income data. The Revenue data used here is four times the quarterly (Mar. 2020) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Neon Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Neon Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Neon Therapeutics (Neon Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
40 Erie Street, Suite 110, Cambridge, MA, USA, 02139
Neon Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The company's pipeline products are NEO-PV-01, NEO-PTC-01, and NEO-SV-01.
Executives
Cary Pfeffer director C/O ELEVEN BIOTHERAPEUTICS, 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142
Jolie Siegel officer: VP, General Counsel C/O NEON THERAPEUTICS, INC., 40 ERIE ST., SUITE 110, CAMBRIDGE MA 02139
Robert Kamen director C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, BOSTON MA 02210
Meryl Zausner director C/O NEON THERAPEUTICS, INC., 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Yasir B. Al-wakeel officer: Chief Financial Officer MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Eric S Lander director 415 MAIN STREET, CAMBRIDGE MA 02142
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080
Robert I Tepper director, 10 percent owner 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Robert B Bazemore director 33 HAYDEN AVE, LEXINGTON MA 02421
Richard Gaynor officer: President of R&D C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Access Industries, Llc other: Affiliate of 10% Owner 730 FIFTH AVENUE, NEW YORK NY 10019
Access Industries Management, Llc other: Affiliate of 10% Owner 730 FIFTH AVENUE, NEW YORK NY 10019
Access Industries Holdings Llc 10 percent owner C/O ACCESS INDUSTRIES MANAGEMENT, LLC., 730 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10019
Clal Biotechnology Industries Ltd. other: See Remarks 3AZRIELI CENTER TRIANGLE TOWER 45 FLOOR, TEL AVIV L3 67023
Len Blavatnik other: Affiliate of 10% Owner C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019

Neon Therapeutics (Neon Therapeutics) Headlines